Small Cell Lung Cancer Extensive Stage Clinical Trial
Official title:
Phase 2 Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer
Patients with extensive-stage small cell lung cancer receive six cycles of chemotherapy(etoposide plus platinum) as first-line treatment,who achieve Complete Response(CR)/Partial Response(PR) will accept small doses of etoposide as maintenance treatment. The objective of this study is to evaluate the progression free survival,overall survival,objective response rate,disease control rate and safety of etoposide as maintenance therapy. Based on previous studies on maintenance therapy in small cell lung cancer,the hypothesis of this study is maintenance therapy using etoposide may improve progression free survival,overall survival for selected patients. The investigators will use the peripheral blood to assess circulating tumor cell and cell-free DNA,which may help us to screen a subgroup of patients with better response to etoposide maintenance therapy.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06030258 -
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05384015 -
Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05745350 -
First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
|
Phase 2 | |
| Completed |
NCT03325816 -
Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05856695 -
A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC)
|
Phase 2 | |
| Recruiting |
NCT05703971 -
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06429696 -
PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT00003496 -
Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT03059667 -
Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03923270 -
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06348797 -
Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
|
Phase 1 | |
| Active, not recruiting |
NCT04462276 -
Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease
|
Phase 2 | |
| Recruiting |
NCT05680922 -
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT04967625 -
A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC
|
Phase 2 | |
| Recruiting |
NCT04659785 -
A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04670445 -
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
|
N/A | |
| Not yet recruiting |
NCT05066945 -
Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients
|
||
| Recruiting |
NCT05945745 -
Molecular Analysis and Treatment Options of SCLC
|
||
| Not yet recruiting |
NCT03755115 -
SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT05027867 -
KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
|
Phase 2 |